RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
NEW YORK, Dec. 16, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Taro Pharmaceutical Industries Ltd. (“Taro Pharmaceutical”) (NYSE:TARO) between July 3, 2014 through September 9, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/taro-pharmaceutical-industries-ltd
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Taro Pharmaceutical made false and/or misleading statements and/or failed to disclose material information, including that since 2014, Taro Pharmaceutical has violated federal antitrust laws by colluding with other pharmaceutical companies to keep the price of generic products artificially high.
On September 9, 2016, Taro Pharmaceutical disclosed the receipt of grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing. Then on October 17, 2016, an antitrust class action was filed against Taro Pharmaceutical and several other companies alleging they have engaged in the price-fixing of the generic drug Clobetasol since 2014.
If you suffered a loss in Taro Pharmaceutical you have until December 27, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
